Chickenpox

Summary

Chickenpox (MONDO:0005700) is a disease with 8 GWAS associations across 10 studies and 117 clinical trials. Top therapeutic interventions include streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197, valacyclovir, and acyclovir. A subtype of varicella zoster infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 8
• Clinical trials: 117

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chickenpox
Mondo ID	MONDO:0005700
EFO	EFO:0007204
MeSH	D002644
DOID	DOID:8659
ICD-10-CM	B01
NCIT	C97132
SNOMED CT	38907003
UMLS	C0008049
MedGen	2995
Is cancer (heuristic)	no

Also known as: chicken pox · chicken pox infection · chickenpox · Varicella · varicella

Data availability: 8 GWAS associations (10 studies).

Disease family

This is a subtype of varicella zoster infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Herpesviridae infectious disease › varicella zoster infection › chickenpox

Related subtypes (3): herpes zoster, herpes zoster dermatitis, herpetic vulvovaginitis

Genetics & variants

GWAS landscape

8 GWAS associations across 10 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr3:15420858	2e-08		T	2.12
chr16:88317860	3e-08		T	0.5
chr3:12693013	3e-08		C	2.71
chr8:115727806	3e-08		ATCTCTCTCTCTCTC	2.67
chr10:2760750	4e-08		A	0.53
chr16:15828552	4e-08		T	0.5
chr2:12151380	4e-08		T	2.28
chr6:73712474	4e-08		C	1.24

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90473048	UK Biobank Whole-Genome Sequencing Consortium	2025	22,029	436,411	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667806	UK Biobank Whole-Genome Sequencing Consortium	2025	22,029	436,411	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90077947	Backman JD	2021	7,564	324,190	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081933	Backman JD	2021	7,564	324,190	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90077948	Backman JD	2021	6,575	322,477	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081934	Backman JD	2021	6,575	322,477	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90726645	Kim HI	2026	1,875	42,151	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90473049	UK Biobank Whole-Genome Sequencing Consortium	2025	234	9,379	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90473047	UK Biobank Whole-Genome Sequencing Consortium	2025	208	9,007	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90435535	Zhou W	2018	65	403,316	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	8

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	8

Functional consequences

Consequence	Count
unknown	8

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr3:15420858							2e-08	Tier 4: intronic/intergenic
chr16:88317860							3e-08	Tier 4: intronic/intergenic
chr3:12693013							3e-08	Tier 4: intronic/intergenic
chr8:115727806							3e-08	Tier 4: intronic/intergenic
chr10:2760750							4e-08	Tier 4: intronic/intergenic
chr16:15828552							4e-08	Tier 4: intronic/intergenic
chr2:12151380							4e-08	Tier 4: intronic/intergenic
chr6:73712474							4e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Acyclovir	Approved (phase 4)
Varicella Zoster Virus, Live Attenuated	Approved (phase 4)
Rubella Virus Vaccine Live	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 117.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	56
PHASE4	22
Not specified	17
PHASE2	14
PHASE1	5
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05095701	PHASE4	ENROLLING_BY_INVITATION	An Immunity Persistence Study of Live Attenuated Varicella Vaccine
NCT06484686	PHASE4	ENROLLING_BY_INVITATION	An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine
NCT06891872	PHASE4	NOT_YET_RECRUITING	Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine
NCT00126997	PHASE4	COMPLETED	Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00326183	PHASE4	COMPLETED	Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
NCT00432731	PHASE4	COMPLETED	Safety Study of a Refrigerator-stable Formulation of VARIVAX®
NCT00830648	PHASE4	COMPLETED	Safety of a Second Dose of Biken’s Varicella Vaccine
NCT01684072	PHASE4	COMPLETED	Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin
NCT01815073	PHASE4	COMPLETED	Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine
NCT01817270	PHASE4	COMPLETED	Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine
NCT01830283	PHASE4	UNKNOWN	The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination
NCT01866566	PHASE4	UNKNOWN	The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination
NCT01982409	PHASE4	UNKNOWN	Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children
NCT02146469	PHASE4	UNKNOWN	Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine
NCT02173899	PHASE4	COMPLETED	Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
NCT03330171	PHASE4	UNKNOWN	Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine
NCT04384016	PHASE4	COMPLETED	Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old
NCT05460429	PHASE4	UNKNOWN	Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus
NCT05470855	PHASE4	UNKNOWN	Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province
NCT05526820	PHASE4	COMPLETED	A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine
NCT05952505	PHASE4	UNKNOWN	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
NCT06987942	PHASE4	COMPLETED	Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
NCT05015686	PHASE3	ENROLLING_BY_INVITATION	Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
NCT05669625	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine
NCT06693895	PHASE3	RECRUITING	A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
NCT06740630	PHASE3	RECRUITING	A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06806137	PHASE3	RECRUITING	A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
NCT06855160	PHASE3	RECRUITING	A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT07054099	PHASE3	RECRUITING	A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
NCT07415252	PHASE3	NOT_YET_RECRUITING	SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
NCT07473427	PHASE3	NOT_YET_RECRUITING	Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial
NCT07475000	PHASE3	RECRUITING	Second Dose of Varicella Vaccine in Healthy Children
NCT00002315	PHASE3	COMPLETED	A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
NCT00002358	PHASE3	COMPLETED	A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
NCT00092391	PHASE3	COMPLETED	A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
NCT00092430	PHASE3	COMPLETED	Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
NCT00098046	PHASE3	COMPLETED	Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
NCT00109343	PHASE3	COMPLETED	V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
NCT00127010	PHASE3	COMPLETED	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00127023	PHASE3	COMPLETED	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197	4	4
VALACYCLOVIR	4	4
ACYCLOVIR	4	2
SORIVUDINE	4	2
FAMCICLOVIR	4	1
RUBELLA VIRUS VACCINE LIVE	3	2
NETIVUDINE	3	1
VARICELLA-ZOSTER IMMUNE GLOBULIN	1	1